Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
4 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Unicycive Therapeutics, Inc.’s names, not what it holds today.
Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and none in 2023
Applications published
11
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
UNICYCIVE THERAPEUTICS INC. its own name
named as the applicant on its applications, in US
10 publishedUNICYCIVE THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 26, 2025 | 12,396,989 | Nicorandil derivatives | Pharmaceuticals | UNICYCIVE THERAPEUTICS, INC. |
| Aug 5, 2025 | 12,377,082 | Nicorandil derivatives | Pharmaceuticals | UNICYCIVE THERAPEUTICS, INC. |
| Jul 16, 2024 | 12,036,211 | Nicorandil derivatives | Pharmaceuticals | UNICYCIVE THERAPEUTICS, INC. |
| Aug 9, 2022 | 11,406,663 | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use | Pharmaceuticals | UNICYCIVE THERAPEUTICS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 18, 2025 | 2025/0288608 | LANTHANUM CARBONATE HYDROXIDE, LANTHANUM OXYCARBONATE AND METHODS OF THEIR MANUFACTURE AND USE | Pharmaceuticals | UNICYCIVE THERAPEUTICS INC. |
| Jul 17, 2025 | 2025/0228891 | COMBINATIONS CONTAINING OXYLANTHANUM CARBONATE FOR TREATING HYPERPHOSPHATEMIA | Pharmaceuticals | UNICYCIVE THERAPEUTICS INC. |
| May 22, 2025 | 2025/0161282 | PHARMACEUTICAL PYRIDYL COMPOSITIONS FOR TREATING AND PREVENTING DELAYED GRAFT FUNCTION | Pharmaceuticals | UNICYCIVE THERAPEUTICS INC. |
| May 8, 2025 | 2025/0145571 | AMINO ACID PRODRUGS OF NICORANDIL | Pharmaceuticals | UNICYCIVE THERAPEUTICS INC. |
| Jan 2, 2025 | 2025/0002458 | SALT FORMS OF NICORANDIL DERIVATIVE | Organic fine chemistry | UNICYCIVE THERAPEUTICS INC. |
| Nov 28, 2024 | 2024/0390348 | NICORANDIL DERIVATIVES | Pharmaceuticals | UNICYCIVE THERAPEUTICS INC. · patent 12,396,989 granted from it |
| Oct 5, 2023 | 2023/0310398 | NICORANDIL DERIVATIVES | Pharmaceuticals | UNICYCIVE THERAPEUTICS INC. · patent 12,036,211 granted from it |
| Nov 3, 2022 | 2022/0347210 | Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and Use | Pharmaceuticals | UNICYCIVE THERAPEUTICS, INC. |
| Aug 25, 2022 | 2022/0265630 | NICORANDIL DERIVATIVES | Pharmaceuticals | UNICYCIVE THERAPEUTICS INC. · patent 12,377,082 granted from it |
| Mar 17, 2022 | 2022/0079927 | NICORANDIL DERIVATIVES | Pharmaceuticals | UNICYCIVE THERAPEUTICS INC. |
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Organic fine chemistry 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.